Propositions

Belonging to the thesis

Non-coding RNAs in eccentric cardiac remodeling and heart failure

By Leonne E Philippen

1. Targeting key players in the Cardiotrophin-1 pathway can prevent eccentric hypertrophy of the heart. (This thesis)

2. MiR-148a acts as a molecular switch between eccentric and concentric hypertrophy, suggesting an attractive target for pharmaceutical interventions. (This thesis)

3. The long non-coding RNA Bigheart can be a pioneer IncRNA for therapeutic targeting due to its function in regulating cardiomyocyte hypertrophic remodeling by affecting RNA splicing and conservation of its sequence between species. (This thesis)

4. Eccentric hypertrophy is the last step of remodeling before heart failure. (This thesis)

5. Understanding the molecular mechanisms underlying heart failure leads to better treatment options.

6. The final 1.6 km of the marathon represents less than 5% of the total distance yet accounts for almost 50% of the sudden cardiac deaths. (BMJ 2007;335;1275-1277)

7. Pharmacological inhibition of microRNA expression and activity is a feasible therapeutic strategy for patients. (Valorization)

8. The larger the island of knowledge, the longer the shoreline of wonder. (Ralph W. Sockman)